An Immunological Glance on Pancreatic Ductal Adenocarcinoma

An Immunological Glance on Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Different factors such as mutational landscape, intra- and intertumoral heterogeneity, stroma, and immune cells impact carcinogenesis of PDAC associated with an immunosuppressive microenvironment. Different cell types with partly...

Full description

Bibliographic Details
Main Authors:	Michael Karl Melzer, Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Christian Bolenz, Alexander Kleger
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	International Journal of Molecular Sciences
Subjects:	PDAC immunotherapy pancreatic cancer immune checkpoints immune microenvironment
Online Access:	https://www.mdpi.com/1422-0067/21/9/3345

Similar Items

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
by: Jingchang Zhang, et al.
Published: (2022-07-01)

Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies
by: Songyu Guo, et al.
Published: (2024-03-01)

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
by: Etienne D. Foucher, et al.
Published: (2018-05-01)

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
by: Sona Ciernikova, et al.
Published: (2020-12-01)

Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma
by: Nadine Sperb, et al.
Published: (2020-07-01)

The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma
by: Yaojie Fu, et al.
Published: (2018-02-01)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
by: Yan Li, et al.
Published: (2022-01-01)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
by: Florian N. Loch, et al.
Published: (2023-01-01)

High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment
by: Hassan Sadozai, et al.
Published: (2024-03-01)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
by: Eric M. Anderson, et al.
Published: (2021-11-01)

Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
by: Benjamin M. MacCurtain, et al.
Published: (2021-06-01)

Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma
by: Ann Mary Joseph, et al.
Published: (2024-02-01)

Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma
by: Yangyang Guo, et al.
Published: (2023-06-01)

Sonic Hedgehog Ligand: A Role in Formation of a Mesenchymal Niche in Human Pancreatic Ductal Adenocarcinoma
by: Francesca Saini, et al.
Published: (2019-05-01)

Galectins Are Central Mediators of Immune Escape in Pancreatic Ductal Adenocarcinoma
by: Zhengting Jiang, et al.
Published: (2022-11-01)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
by: Natalia Michalak, et al.
Published: (2023-06-01)

Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies
by: Xiaoying Li, et al.
Published: (2024-02-01)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
by: Derya Kabacaoglu, et al.
Published: (2018-08-01)

Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
by: Tina Daunke, et al.
Published: (2023-06-01)

Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification
by: Yi Chen, et al.
Published: (2022-01-01)

PKM2 is not required for pancreatic ductal adenocarcinoma
by: Alissandra L Hillis, et al.
Published: (2018-10-01)

Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
by: Darya Javadrashid, et al.
Published: (2021-04-01)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
by: Wayne Croft, et al.
Published: (2023-06-01)

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
by: Conner Hartupee, et al.
Published: (2024-02-01)

Utilising Pancreatic Exocrine Insufficiency in the Detection of Resectable Pancreatic Ductal Adenocarcinoma
by: Declan McDonnell, et al.
Published: (2023-12-01)

Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
by: Iranzu González-Borja, et al.
Published: (2021-11-01)

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01)

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
by: Ahmad Ali, et al.
Published: (2022-08-01)

GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma
by: Sen Yang, et al.
Published: (2022-08-01)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
by: Xianlong Chen, et al.
Published: (2022-07-01)

Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma
by: Aditi Kothari, et al.
Published: (2021-05-01)

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography
by: Ruth González-Gómez, et al.
Published: (2021-03-01)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
by: Dongjie Chen, et al.
Published: (2021-10-01)

A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma
by: Benedetta Ferrara, et al.
Published: (2022-09-01)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
by: Rong Tang, et al.
Published: (2021-03-01)

Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
by: Maarten F. Bijlsma, et al.
Published: (2022-04-01)

Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma
by: Hao Yuan, et al.
Published: (2021-12-01)

The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma
by: Alexander A. Lekan, et al.
Published: (2024-01-01)